OSCR
Oscar Health, Inc.
OSCR has the edge over TGTX overall, supported by stronger modeled upside and lower modeled downside.
TGTX
TG Therapeutics, Inc.
TGTX's outlook is improving, though it still trails on the overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TGTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
TGTX's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over TGTX in the historical PE scenario, which offers more potential upside but is not a forecast.
TGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $7.91 | -88% |
| Forward | 26x | $64.56 | — |
| Fair | 39x | $25.80 | -60% |
| Current | 98x | $64.56 | — |
| Expensive | 148x | $97.38 | +51% |
Historical ranges are pointers, not guarantees.
TGTX's PE is in its expensive range at 98x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its fair range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TGTX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for TGTX, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
TGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.52 | +282% |
| Q3 2026 | $0.66 | -76% |
| Q2 2026 | $2.74 | +621% |
| Q1 2026 | $2.86 | +1044% |
| Q4 2025 | $2.77 | +1747% |
| Q3 2025 | $2.79 | +$2.89 |
| Q2 2025 | $0.38 | -38% |
| Q1 2025 | $0.25 | +8.7% |
| Q4 2024 | $0.15 | +650% |
TGTX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.9M | +61% |
| Q2 2026 | $240.3M | +70% |
| Q1 2026 | $204.9M | +70% |
| Q4 2025 | $192.6M | +78% |
| Q3 2025 | $161.7M | +93% |
| Q2 2025 | $141.1M | +92% |
| Q1 2025 | $120.9M | +90% |
| Q4 2024 | $108.2M | +146% |
TGTX has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +15 points |
| Q2 2026 | 9% | -16 points |
| Q1 2026 | 17% | +9.9 points |
| Q4 2025 | 26% | -1.5 points |
| Q3 2025 | 18% | +3.3 points |
| Q2 2025 | 25% | +13 points |
| Q1 2025 | 7.1% | +22 points |
| Q4 2024 | 28% | +56 points |
TGTX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
TGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44.9M | +$68.2M |
| Q2 2026 | $39M | +427% |
| Q1 2026 | -$17.9M | +$10.8M |
| Q4 2025 | $19.6M | +$45.3M |
| Q2 2025 | $7.4M | +34% |
| Q1 2025 | -$28.7M | -$20.5M |
| Q4 2024 | -$25.7M | -$12.5M |
| Q4 2023 | -$13.2M | +$10.7M |
TGTX has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.4M shares |
| 1 year | -3.2% | -5.1M shares |
| 3 years | 0% | +53.3K shares |
| 5 years | +18% | +23.6M shares |
| Available history | +76% | +67.6M shares |
TGTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100M |
| Q2 2026 | — |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $78.2M |
| Q2 2025 | $6.9M |
| Q1 2025 | $6.1M |
| Q4 2024 | $6.6M |
TGTX spent $200M buying back its own shares over the past year, up 104% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over TGTX on leverage, with a lower net debt burden relative to earnings.
TGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.5x | Healthy |
TGTX's net debt is about 1.6 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 86.3 | Overbought |
TGTX's weekly RSI is 69 (neutral) and its Stochastic is 86 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over TGTX on valuation relative to its sector.
TGTX PE vs Healthcare Sector
| Metric | TGTX | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 75 | 29 | 46 pts above |
TGTX is trading at 98x earnings, a 278% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.6 | 12% above |
| 20 week MA | $55.4 | 17% above |
| 50 week MA | $43.0 | 50% above |
| 100 week MA | $38.7 | 67% above |
| 200 week MA | $28.6 | 126% above |
TGTX is in an uptrend: it's above all five of its weekly moving averages, and 126% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TGTX on returns for 2026, with the stronger performance.
TGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $53.3 | +390% |
| 2021 | $53.3 | $19.4 | -64% |
| 2022 | $19.4 | $8.12 | -58% |
| 2023 | $8.12 | $17.1 | +110% |
| 2024 | $17.1 | $32.5 | +90% |
| 2025 | $32.5 | $30.8 | -5.4% |
| 2026 YTD | $30.8 | $64.6 | +110% |
TGTX's yearly returns have swung widely, from +390% in 2020 to −64% in 2021. It's up 110% so far in 2026.